查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963836

放射性药物市场－全球产业规模、份额、趋势、机会和预测：按类型、来源、最终用户、地区和竞争格局划分，2021-2031年

Radiopharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Source, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球放射性药物市场预计将从 2025 年的 61.2 亿美元成长到 2031 年的 83.2 亿美元，复合年增长率为 5.25%。

这些结合了放射性同位素和药物的製剂在诊断影像检查和标靶治疗介入中都发挥着至关重要的作用。推动其成长的主要因素是全球慢性病（尤其是肿瘤和心血管疾病）发生率的上升，这些疾病需要高度精确的诊断工具。此外，全球人口老化也持续推高了对核子医学的需求，因为老年人通常需要更频繁的监测和介入。根据世界核能学会预测，到2025年，全球每年将进行超过5,000万例核医检查，凸显了这些产品在现代医疗保健体系中的关键作用。

市场概览
预测期 2027-2031
市场规模：2025年 61.2亿美元
市场规模：2031年 83.2亿美元
复合年增长率：2026-2031年 5.25%
成长最快的细分市场 诊断用放射性药物
最大的市场 北美洲

儘管市场成长迅速，但复杂的物流配送仍为分销带来了巨大挑战。许多具有重要临床意义的同位素会发生快速的放射性崩坏，因此供应链必须严格把控时间，即使运输过程中出现轻微延误也可能导致产品过期或报废。由于同位素生产依赖于数量有限的核子反应炉，这种物流脆弱性进一步加剧，造成严重的供应不稳定，并限制了新兴市场对这些关键治疗方法的供应。

市场驱动因素

标靶放射性核种疗法的加速普及正在从根本上改变全球市场，推动产业重心从诊断影像转向精准治疗性介入。与传统的体外放射线治疗不同，这些全身性疗法利用特定的生物标记将放射性物质直接输送到癌细胞，在最大限度地提高疗效的同时，最大限度地保护健康组织。核准药物的强劲收入成长证明了该治疗方法的商业性潜力。根据BioSpace公司2024年10月发布的公告，其前列腺癌药物Pluvicto仅在第三季的销售额就达到了3.86亿美元，年增50%。这项应用凸显了治疗诊断学的临床价值，并巩固了肿瘤学领域向个人化核医学的转变。

同时，政府拨款和私人投资的增加正在缓解核医领域传统的供应链瓶颈，并促进创新。领先的製药公司正积极收购专业的生物技术公司，以确保自身放射性同位素的生产能力并拓展其肿瘤产品组合。例如，根据《製药技术》杂誌2024年2月报道，百时美施贵宝以约41亿美元收购了RaiseBio，从而获得了其基于锕的放射性药物平台。这种策略整合的趋势进一步增强了该产业的长期财务稳定性。Astra Zeneca在2024年宣布，该公司已完成对Fusion Pharmaceuticals的收购，交易金额约24亿美元，这加强了该产业扩大下一代放射性标记化合物规模的努力。

市场挑战

全球放射性药物市场面临许多成长障碍，主要源自于产品分销物流的复杂性和供应链固有的不稳定性。由于放射性药物含有半衰期短的同位素，崩坏极快，无法储存，因此需要严格同步的「准时制」配送模式。这项限制意味着，即使运输过程中出现轻微延误，也可能导致产品过期和经济损失，直接减少可治疗的患者数量，并限制收入潜力。因此，物流基础设施落后地区的医疗机构往往难以获得这些关键的诊断和治疗药物，从而有效地限制了市场的地域覆盖范围。

市场对少数核子反应炉的高度依赖进一步加剧了这种脆弱性，这意味着单一反应器的运作故障可能引发全球危机。据欧洲核医学协会称，2024年关键生产核子反应炉运作的意外延迟导致多个地区关键医用同位素短缺，短缺率从50%到100%不等。如此严重的供应中断迫使医院暂停或推迟手术，削弱了人们对核子医学的信心，并阻碍了整个产业的发展。

市场趋势

新型放射性同位素的商业化正在拓展诊断能力，使诊断手段从镓-68等传统示踪剂转向铜-64等新一代示踪剂。铜-64具有更优异的成像性能和物流优势。这些新型同位素半衰期长，可实现集中生产和广域分销，有效缓解了短寿命示踪剂带来的供应链瓶颈。 Clarity Pharmaceuticals公司在2025年1月预测，光是在美国，第一代PSMA PET影像的市场规模就将达到约20亿美元，凸显了这些先进诊断技术的经济潜力。该公司认为，临床排班柔软性可能会使铜基示踪剂获得显着的市场份额。

同时，纤维母细胞活化蛋白 (FAP) 抑制剂的研发正在肿瘤学领域建立一种新的范式，其标靶不再是恶性细胞本身，而是肿瘤微环境。这种作用机制克服了抗原特异性放射性配体的限制（后者往往仅限于单一适应症），从而实现了对多种上皮肿瘤的泛癌成像和治疗。为了支持业界扩大这种前景广阔的治疗方法的规模，Contract Pharma 于 2025 年 5 月报道称，Ratio Therapeutics 已宣布达成协议，将在犹他州建造一座占地 65,000 平方英尺的工厂，专门用于其 FAP 靶向产品线的垂直整合和商业化生产。这项基础设施投资凸显了 FAP 抑制剂正迅速从实验研究阶段过渡到可规模化的临床应用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球放射性药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（诊断用放射性药物、治疗放射性药物）
    • 供应来源（核子反应炉、迴旋加速器）
    • 依最终使用者（医院/诊所、诊断影像中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美放射性药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲放射性药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区放射性药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲放射性药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲放射性药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球放射性药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • PharmaLogic Holdings LLC
  • Jubilant Radiopharma
  • China Isotope & Radiation Corporation
  • Siemens Healthineers AG
  • SHINE Technologies, LLC
  • Ion Beam Applications SA
  • Global Medical Solutions
  • BWX Technologies. Inc
  • CoquI Radio Pharmaceuticals Corp.
  • Evergreen Theragnostics, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23964

The Global Radiopharmaceuticals Market is projected to expand from USD 6.12 billion in 2025 to USD 8.32 billion by 2031, reflecting a compound annual growth rate of 5.25%. These medicinal formulations, which combine radioactive isotopes with pharmaceutical agents, are essential for both diagnostic imaging and targeted therapeutic interventions. Growth is largely driven by the rising global incidence of chronic diseases, particularly oncology and cardiovascular disorders, which demand high-precision diagnostic tools. Additionally, the aging global demographics sustain demand for nuclear medicine, as elderly populations typically require more frequent monitoring and intervention. According to the World Nuclear Association, more than 50 million nuclear medicine procedures are conducted annually worldwide as of 2025, highlighting the vital role these products play in modern healthcare systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.12 Billion
Market Size 2031USD 8.32 Billion
CAGR 2026-20315.25%
Fastest Growing SegmentDiagnostic Radiopharmaceuticals
Largest MarketNorth America

Despite this growth, the market encounters significant hurdles related to the complex logistics needed for distribution. The rapid radioactive decay of many clinically vital isotopes necessitates a strictly timed supply chain, where even minor transportation delays can lead to product expiration and wastage. This logistical fragility is intensified by a dependence on a limited number of nuclear reactors for isotope production, creating severe supply vulnerabilities and restricting the availability of these essential treatments in emerging markets.

Market Driver

The accelerating adoption of targeted radionuclide therapy is fundamentally transforming the global market, moving the industry's focus from diagnostic imaging toward precision therapeutic interventions. Unlike conventional external beam radiation, these systemic treatments employ specific biomarkers to deliver radioactive payloads directly to cancer cells, maximizing efficacy while sparing healthy tissue. The commercial potential of this modality is demonstrated by the robust revenue growth of approved agents. According to BioSpace in October 2024, the prostate cancer therapy Pluvicto generated $386 million in sales during the third quarter alone, marking a 50% year-over-year increase. This adoption underscores the clinical value of theranostics and confirms the shift toward personalized nuclear medicine in oncology.

Concurrently, increased government funding and private investment in nuclear medicine are addressing historical supply chain limitations and driving innovation. Major pharmaceutical companies are actively acquiring specialized biotechnology firms to secure proprietary radioisotope manufacturing capabilities and broaden their oncology portfolios. For instance, Pharmaceutical Technology reported in February 2024 that Bristol Myers Squibb acquired RayzeBio for approximately $4.1 billion to access its actinium-based radiopharmaceutical platform. This trend of strategic consolidation is further solidifying the sector's long-term financial stability; as noted by AstraZeneca in 2024, the company completed its acquisition of Fusion Pharmaceuticals for roughly $2.4 billion, reinforcing the industry's dedication to scaling next-generation radioconjugates.

Market Challenge

The Global Radiopharmaceuticals Market encounters a significant barrier to growth stemming from the complex logistics of product distribution and the inherent instability of its supply chain. Because radiopharmaceuticals contain isotopes with short half-lives, they decay quickly and cannot be stockpiled, requiring a strictly synchronized "just-in-time" delivery model. This constraint implies that even minor delays in transportation inevitably result in product expiration and financial loss, directly reducing the number of patients treated and curbing revenue potential. As a result, healthcare facilities in regions with underdeveloped logistical infrastructure often struggle to access these critical diagnostics and therapies, effectively limiting the market's geographical reach.

This fragility is further compounded by the market's heavy dependence on a small number of nuclear reactors, where a single operational disruption can precipitate a global crisis. According to Nuclear Medicine Europe, in 2024, unexpected delays in the restart of a major production reactor led to supply shortages of critical medical isotopes ranging from 50% to 100% across various regions. Such severe interruptions compel hospitals to cancel or postpone procedures, undermining confidence in nuclear medicine and hindering the overall progress of the industry.

Market Trends

The commercialization of novel radioisotopes is expanding diagnostic capabilities, shifting beyond legacy agents like Gallium-68 to next-generation options such as Copper-64, which offer superior imaging characteristics and logistical benefits. These novel isotopes possess extended half-lives that support centralized manufacturing and wider geographic distribution, effectively mitigating the supply chain constraints associated with shorter-lived tracers. Highlighting the economic potential of these advanced diagnostics, Clarity Pharmaceuticals noted in January 2025 that the current market for first-generation diagnostic PSMA PET imaging is valued at approximately $2 billion in the U.S. alone, positioning copper-based alternatives to capture significant market share by enhancing clinical scheduling flexibility.

Simultaneously, the development of Fibroblast Activation Protein (FAP) inhibitors is establishing a new paradigm in oncology by targeting the tumor microenvironment rather than malignant cells directly. This mechanism enables pan-cancer imaging and treatment of various epithelial tumors, addressing the limitations of antigen-specific radioligands that are often restricted to single indications. Validating the industry's commitment to scaling this promising modality, Contract Pharma reported in May 2025 that Ratio Therapeutics announced an agreement to construct a 65,000-square-foot facility in Utah dedicated to the vertical integration and commercial production of its FAP-targeted pipeline. This investment in infrastructure underscores the rapid transition of FAP inhibitors from experimental research to scalable clinical solutions.

Key Market Players

  • PharmaLogic Holdings LLC
  • Jubilant Radiopharma
  • China Isotope & Radiation Corporation
  • Siemens Healthineers AG
  • SHINE Technologies, LLC
  • Ion Beam Applications SA
  • Global Medical Solutions
  • BWX Technologies. Inc
  • CoquI Radio Pharmaceuticals Corp.
  • Evergreen Theragnostics, Inc.

Report Scope

In this report, the Global Radiopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiopharmaceuticals Market, By Type

  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals

Radiopharmaceuticals Market, By Source

  • Nuclear Reactors
  • Cyclotrons

Radiopharmaceuticals Market, By End user

  • Hospitals & Clinics
  • Diagnostics imaging centre
  • Others

Radiopharmaceuticals Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiopharmaceuticals Market.

Available Customizations:

Global Radiopharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiopharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals)
    • 5.2.2. By Source (Nuclear Reactors, Cyclotrons)
    • 5.2.3. By End user (Hospitals & Clinics, Diagnostics imaging centre, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Radiopharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Source
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Radiopharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Source
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Radiopharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Source
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Radiopharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Source
        • 6.3.3.2.3. By End user

7. Europe Radiopharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Source
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Radiopharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Source
        • 7.3.1.2.3. By End user
    • 7.3.2. France Radiopharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Source
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Radiopharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Source
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Radiopharmaceuticals Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Source
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Radiopharmaceuticals Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Source
        • 7.3.5.2.3. By End user

8. Asia Pacific Radiopharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Source
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Radiopharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Source
        • 8.3.1.2.3. By End user
    • 8.3.2. India Radiopharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Source
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Radiopharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Source
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Radiopharmaceuticals Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Source
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Radiopharmaceuticals Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Source
        • 8.3.5.2.3. By End user

9. Middle East & Africa Radiopharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Source
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Radiopharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Radiopharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Radiopharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By End user

10. South America Radiopharmaceuticals Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Source
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Radiopharmaceuticals Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Radiopharmaceuticals Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Radiopharmaceuticals Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Radiopharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. PharmaLogic Holdings LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Jubilant Radiopharma
  • 15.3. China Isotope & Radiation Corporation
  • 15.4. Siemens Healthineers AG
  • 15.5. SHINE Technologies, LLC
  • 15.6. Ion Beam Applications SA
  • 15.7. Global Medical Solutions
  • 15.8. BWX Technologies. Inc
  • 15.9. CoquI Radio Pharmaceuticals Corp.
  • 15.10. Evergreen Theragnostics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer